Leerink Partners analyst Daina Graybosch maintained a Buy rating on 2seventy bio (TSVT – Research Report) on April 26. The company’s shares closed yesterday at $4.59.
Graybosch covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and BioNTech SE. According to TipRanks, Graybosch has an average return of -8.7% and a 33.81% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 2seventy bio with a $12.00 average price target.
The company has a one-year high of $12.69 and a one-year low of $1.54. Currently, 2seventy bio has an average volume of 1.46M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
2seventy bio (TSVT) Company Description:
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
Read More on TSVT:
- 2seventy Bio price target raised to $12 from $9 at Citi
- 2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
- Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
- Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
- 2seventy bio Finalizes Asset Sale and Executive Transition
